Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial-Reference-Cited by-同舟云学术

Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial

Published:2023-02 Issue:2 Volume:24 Page:162-174
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Rodler Eve,Sharma Priyanka,Barlow William E,Gralow Julie R,Puhalla Shannon L,Anders Carey K,Goldstein Lori,Tripathy Debu,Brown-Glaberman Ursa A,Huynh Thu-Tam,Szyarto Christopher S,Godwin Andrew K,Pathak Harsh B,Swisher Elizabeth M,Radke Marc R,Timms Kirsten M,Lew Danika L,Miao Jieling,Pusztai Lajos,Hayes Daniel F,Hortobagyi Gabriel N

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer;Liedtke;J Clin Oncol,2008

2. Triple-negative breast cancer: clinical features and patterns of recurrence;Dent;Clin Cancer Res,2007

3. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing;Sharma;Breast Cancer Res Treat,2014

4. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer;Couch;J Clin Oncol,2015

5. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial;Tutt;Nat Med,2018

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DRN-CDR: A cancer drug response prediction model using multi-omics and drug features;Computational Biology and Chemistry;2024-10

2. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24

3. Neurological toxicities with poly (ADP-ribose) polymerase inhibitors in cancer patients: a systematic review and meta-analysis;Journal of Chemotherapy;2024-08-23

4. Impact of Molecular Profiling on Therapy Management in Breast Cancer;Journal of Clinical Medicine;2024-08-23

5. Strategies for the prevention or reversal of PARP inhibitor resistance;Expert Review of Anticancer Therapy;2024-08-20